Coronavirus (COVID-19) Collection
Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness
Some patients with COVID-19 pneumonia display clinical and laboratory signs of a hyperinflammatory response, including markedly elevated serum C-reactive protein (CRP) and ferritin levels, followed by rapid respiratory status decompensation and progression to multisystem organ failure. These observations led to the use of varying doses of corticosteroids and targeted anti-cytokine agents, including anakinra, an anti-interleukin (IL)-1 treatment, early in the pandemic.High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness
The optimal dose of corticosteroids in the treatment of SARS-CoV-2 infection is uncertain, particularly among patients with severe respiratory impairment (The WHO Rapid Evidence Appraisal for COVID-19 Therapies [REACT] Working Group, 2020), and practice remains varied. Recent randomized controlled trials (RCTs) that compared high (12 mg) to low (6 mg) doses of dexamethasone in patients hospitalized for severe COVID-19 pneumonia found no difference in mortality (Bouadma et al., 2022) or were inconclusive (COVID STEROID 2 Trial Group et al.
